Calls for Reduced Mpox Testing Prices Amid Global Health Challenges
Global health advocates are urging Cepheid to reduce mpox test prices from $20 to $5, aiming to improve access in low-income countries like the Democratic Republic of Congo. Recent cases of mpox and bird flu in the U.S. highlight the urgent need for equitable healthcare solutions and enhanced disease surveillance. As the world faces these health challenges, the call for affordable testing and treatment options intensifies.
Bavarian Nordic Reports Revenue Growth and Strategic Advances in Q3 2024
Bavarian Nordic A/S reports strong interim financial results for the first nine months of 2024, with total revenue reaching DKK 3,622 million and an 18% increase in its Travel Health division. The company maintains its full-year guidance amidst uncertainties related to mpox vaccine logistics, while securing DKK 2,400 million in vaccine orders for 2025. CEO Paul Chaplin highlights the company’s commitment to global health and its proactive measures in combating the mpox outbreak.
Bavarian Nordic Submits Chikungunya Vaccine for Approval in Europe
Bavarian Nordic has submitted its chikungunya vaccine for approval in Europe, following a similar application in the US. This strategic move aims to combat the spread of the mosquito-borne viral disease and improve global health initiatives. Stay tuned for updates on the potential approval in the first half of 2025.